Skip to main content
Ensol Biosciences Inc. logo

Ensol Biosciences Inc. — Investor Relations & Filings

Ticker · 140610 ISIN · KR7140610007 KO Manufacturing
Open in API
Filings indexed 257 across all filing types
Latest filing 2025-03-11 Proxy Solicitation & In…
Country KR South Korea
Listing KO 140610

About Ensol Biosciences Inc.

https://www.ensolbio.co.kr/eng/

Ensol Biosciences Inc. is a biopharmaceutical company focused on developing innovative drugs for diseases with limited or no therapeutic alternatives. The company leverages a bio big data and AI-driven platform for its research and development activities. A core area of its technology involves Protein-Protein Interaction (PPI)-regulating short peptide drugs, which are designed for local injection to maximize therapeutic effects and minimize systemic side effects through high specificity and a short half-life in the blood. The company's pipeline targets a range of medical unmet needs, including degenerative disc disease, osteoarthritis, cancer, and neurodegenerative disorders like Alzheimer's disease. Key clinical-stage assets include E1K for osteoarthritis (preparing for Phase 3) and C1K, an anticancer combination therapy (Phase 1).

Recent filings

Filing Released Lang Actions
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집 결의) issued by Ensol Biosciences. It outlines the date, location, and specific agenda items for the upcoming meeting, including the approval of financial statements, election of directors and auditors, and remuneration limits. This type of document is designed to inform shareholders of the meeting and solicit their participation/votes, which aligns with the definition of a Proxy Solicitation & Information Statement.
2025-03-11 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) issued by Ensol Biosciences. It contains the agenda for the upcoming Annual General Meeting (AGM), including items such as the approval of financial statements, election of directors, and remuneration limits. It also includes detailed proxy information, such as voting procedures, electronic voting instructions, and candidate profiles for board positions. This document is a standard proxy statement used to solicit shareholder votes for an upcoming meeting, which falls under the 'Proxy Solicitation & Information Statement' category.
2025-03-11 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (DART system) used to provide shareholders with information regarding upcoming general meetings, including agenda items like director appointments, financial statement approval, and stock option grants. This falls under the category of Proxy Solicitation & Information Statement.
2025-03-11 Korean
[기재정정]의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Proxy Solicitation Reference Document) and is a formal filing by Ensol Biosciences. It contains detailed information regarding the upcoming Annual General Meeting (AGM), including agenda items such as the approval of financial statements, election of directors, and remuneration limits. This document is specifically designed to solicit proxies from shareholders for the meeting, which aligns perfectly with the definition of a Proxy Solicitation & Information Statement (PSI).
2025-03-11 Korean
[기재정정]주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) regarding the 'Decision to Issue Convertible Bonds' (전환사채권 발행결정) and specifically details a 'Correction Report' (정정신고) for previously filed information. This document outlines the terms of the convertible bonds, including put/call options, interest rates, and conversion price adjustments. In the context of Korean corporate filings (DART), this is a regulatory filing related to capital structure changes and financing, which falls under the 'Capital/Financing Update' category.
2025-02-28 Korean
[기재정정]주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) from Ensol Biosciences regarding the 'Decision to Issue Convertible Bonds' (전환사채권 발행결정). It details specific terms of a financial instrument, including interest rates, conversion prices, and put/call option conditions, and includes a 'Correction Report' (정정신고) section updating previous terms. This falls under the category of capital and financing updates.
2025-02-28 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.